IP Library › Granted Patent US 12,610,974
Granted Patent B2
US 12,610,974 · App. 18/487,272 · Granted Apr 28, 2026

Capsule clusters for oral consumption

Inventors: Danielle R. Crawford (Chester, VA); Shon Gedevani (Richmond, VA); William R. Sweeney (Richmond, VA); Chris Irving (Richmond, VA)
Assignee: Philip Morris USA Inc.
A23L27/72A23L29/212A23L29/25A23L29/256A23L33/15A23P10/30A23P30/10A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,610,974
App. No.
18/487,272
Granted
Apr 28, 2026
Kind
B2
Abstract

An oral product includes a matrix including a mixture of a plurality of capsules, a powdered component, a viscous component and a binder and wherein the matrix is molded into a shape. In a preferred embodiment, the capsules provide functional and flavorful ingredients. In an embodiment, the matrix is enclosed in a porous material that forms a pouch.

Claims (48)

1 . A method for preparing an oral product, the method comprising:

forming a single layer coating on a matrix,

the single layer coating including:

a soluble, non-cross-linked component, and

an insoluble, cross-linked component,

the matrix including:

a plurality of capsules, and

a binder,

the single layer coating and matrix together defining the oral product.

2 . The method of claim 1 , further comprising:

preparing the matrix by contacting the plurality of capsules and binder.

3 . The method of claim 2 , wherein the preparing the matrix further comprises:

adding a powder component, the powder component including dry sour cream, baking soda, powdered sugar, powdered cocoa, powdered spices, powdered herbs, tea, tea extracts, guarana, or any combination thereof.

4 . The method of claim 3 , wherein the preparing the matrix further comprises:

contacting the powder component to the plurality of capsules and the binder.

5 . The method of claim 2 , wherein the preparing the matrix further comprises:

adding a viscous substance having a water activity of greater than or equal to 0.4 aw to less than or equal to 0.8 aw.

6 . The method of claim 5 , wherein the viscous substance includes honey, molasses, syrups, or any combination thereof.

7 . The method of claim 1 , further comprising:

molding the matrix to form a preform.

8 . The method of claim 7 , further comprising:

contacting the preform to a polymer solution including the soluble, non-cross-linked component and the insoluble, cross-linked component to coat the preform.

9 . The method of claim 8 , wherein the contacting the preform comprises:

dipping the preform in the polymer solution.

10 . The method of claim 8 , further comprising:

cross-linking the insoluble, cross-linked component using a monovalent metal ion salt or a bivalent metal ion salt.

11 . The method of claim 10 , further comprising:

after the cross-linking, drying the oral product to remove excess moisture until the oral product has a water activity of less than or equal to 0.87 aw.

12 . The method of claim 1 , wherein the forming of the single layer coating on the matrix includes:

dispersing the soluble, non-cross-linked component and the insoluble, cross-linked component in one or more patterns to form the coating.

13 . The method of claim 1 , wherein the single layer coating further comprises:

an additive, the additive including natural sweeteners, artificial sweeteners, chemesthesis agents, or any combination thereof.

14 . The method of claim 13 , wherein

the natural or artificial sweeteners include xylose, ribose, sucrose, maltose, fructose, glucose, mannose, sucralose, acesulfame K, neotame, aspartame, or any combination thereof, and

the chemesthesis agent includes capsaicin, tannins, mustard oil, wintergreen oil, cinnamon oil, allicin, quinine, citric acid, salt, or any combination thereof.

15 . The method of claim 1 , wherein at least a portion of the plurality of capsules includes a plurality of functional capsules, a plurality of flavor capsules, or both a plurality of functional capsules and a plurality of flavor capsules.

16 . The method of claim 15 , wherein

the plurality of functional capsules includes a chemesthesis agent, an antioxidant, a vitamin, a soothing agent, an energizing agent, an alerting agent, a calming agent, or any combination thereof, and

the plurality of flavor capsules include pomegranate, acai, raspberry, blueberry, strawberry, cranberry, menthol, peppermint, spearmint, bourbon, scotch, whiskey, cognac, hydrangea, lavender, chocolate, licorice, citrus, apple, peach, pear, cherry, plum, orange, grapefruit, gamma octalactone, vanillin, ethyl vanillin, cinnamon, clove, nutmeg, sage, anise, fennel, methyl salicylate, linalool, jasmine, coffee, bergamot oil, geranium oil, lemon oil, ginger oil, guarana, tea herbs, tea extracts, or any combination thereof.

17 . The method of claim 16 , wherein

the soothing agent includes chamomile, lavender, jasmine, or any combination thereof,

the energizing agent includes caffeine, taurine, guarana, vitamin B6, vitamin B12, or any combination thereof, and

the chemesthesis agent includes mint, menthol, capsaicin, cinnamon, pepper, or any combination thereof.

18 . The method of claim 1 , wherein the plurality of capsules include an effervescent agent.

19 . The method of claim 1 , wherein the binder includes sodium alginate, sugar, agar, guar gum, flour, water, maltodextrin, or any combination thereof.

20 . The method of claim 1 , wherein

the soluble, non-cross-linked component includes starch, dextrin, gum arabic, guar gum, chitosan, cellulose, polyvinyl alcohol, polylactide, soy protein, whey protein, or any combination thereof, and

the insoluble, cross-linked component includes one or more modified polysaccharides with cross-linkable functional groups.

Continuity (7)
Continuation 17003099 · Aug 26, 2020
Continuation 15971160 · May 4, 2018
Continuation 15425601 · Feb 6, 2017
Continuation 14573524 · Dec 17, 2014
Division 12155634 · Jun 6, 2008
Provisional Application 60929028 · Jun 8, 2007
Related Publication 20240057648A1 · Feb 22, 2024
References Cited (31)
US 3757798A · Lambert · 1973 [cited by applicant]
US 5167244A · Kjerstad · 1992 [cited by applicant]
US 5332595A · Gaonkar · 1994 [cited by applicant]
US 5897897A · Porzio et al. · 1999 [cited by applicant]
US 6162516A · Derr · 2000 [cited by applicant]
US 6652895B2 · Porzio et al. · 2003 [cited by applicant]
US 8469036B2 · Williams et al. · 2013 [cited by applicant]
US 8627828B2 · Strickland et al. · 2014 [cited by applicant]
US 8940344B2 · Crawford et al. · 2015 [cited by applicant]
US 20030026874A1 · Porzio et al. · 2003 [cited by applicant]
US 20030224090A1 · Pearce et al. · 2003 [cited by applicant]
US 20040247649A1 · Pearce et al. · 2004 [cited by applicant]
US 20040247744A1 · Pearce et al. · 2004 [cited by applicant]
US 20040247746A1 · Pearce et al. · 2004 [cited by applicant]
US 20050003048A1 · Pearce et al. · 2005 [cited by applicant]
US 20050061339A1 · Hansson et al. · 2005 [cited by applicant]
US 20050067726A1 · Yan et al. · 2005 [cited by applicant]
US 20050095338A1 · Fernandes et al. · 2005 [cited by applicant]
US 20050100640A1 · Pearce · 2005 [cited by applicant]
US 20050244521A1 · Strickland et al. · 2005 [cited by applicant]
US 20060073190A1 · Carroll et al. · 2006 [cited by applicant]
US 20060191548A1 · Strickland · 2006 [cited by examiner]
US 20080202533A1 · Mishra et al. · 2008 [cited by applicant]
EP 1120044A1 · 2001 [cited by applicant]
WO WO9818610A1 · 1998 [cited by applicant]
WO WO0135925A1 · 2001 [cited by applicant]
WO WO0200033A1 · 2002 [cited by applicant]
WO WO0604480A1 · 2006 [cited by applicant]
WO WO2006082536A1 · 2006 [cited by applicant]
WO WO2007057789A2 · 2007 [cited by applicant]
WO WO2007057791A2 · 2007 [cited by applicant]